Insider Selling: HilleVax, Inc. (NASDAQ:HLVX) Director Sells $10,230.45 in Stock

Posted by MarketBeat News on May 6th, 2024

HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) Director Aditya Kohli sold 723 shares of HilleVax stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $14.15, for a total value of $10,230.45. Following the completion of the sale, the director now owns 782,878 shares in the company, valued at $11,077,723.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Aditya Kohli also recently made the following trade(s):

On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The shares were sold at an average price of $14.03, for a total value of $2,455.25.
On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.44, for a total value of $86,640.00.
On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.93, for a total transaction of $89,580.00.
On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00.
On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $17.66, for a total value of $105,960.00.
On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total value of $111,960.00.
On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $18.95, for a total value of $113,700.00.
On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $15.05, for a total value of $90,300.00.
On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.88, for a total value of $89,280.00.
On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.32, for a total value of $91,920.00.

HilleVax Stock Performance

NASDAQ:HLVX opened at $13.61 on Monday. HilleVax, Inc. has a 52 week low of $9.94 and a 52 week high of $20.22. The company has a fifty day simple moving average of $15.62 and a two-hundred day simple moving average of $14.70. The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The company has a market cap of $676.69 million, a price-to-earnings ratio of -4.48 and a beta of 0.79.

Want More Great Investing Ideas?

HilleVax (NASDAQ:HLVX – Get Free Report) last released its earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.02. As a group, equities analysts anticipate that HilleVax, Inc. will post -3.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of HilleVax in a research note on Thursday, March 21st.

Check Out Our Latest Stock Report on HLVX

Hedge Funds Weigh In On HilleVax

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Catalys Pacific LLC acquired a new stake in HilleVax in the fourth quarter valued at approximately $21,009,000. Franklin Resources Inc. raised its holdings in shares of HilleVax by 4.1% in the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after purchasing an additional 71,938 shares in the last quarter. Swiss National Bank lifted its position in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares during the last quarter. abrdn plc purchased a new stake in shares of HilleVax during the 4th quarter worth $433,000. Finally, SG Americas Securities LLC purchased a new position in HilleVax in the fourth quarter valued at $139,000. 86.42% of the stock is owned by institutional investors and hedge funds.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.